当前位置:首页 / 科学研究 / 辅助中心 / 正文

抗体中心

田欣欣 博士
抗体中心主任

Director of the Antibody Center

Phone: 010-80726688-8331

E-mail:tianxinxin@nibs.ac.cn

中心主任简介:


教育经历Education

2019 北京大学、清华大学和北京生命科学研究所联合培养博士研究生项目 生物化学与分子生物学 博士学位

Ph.D. Biochemistry and Molecular Biology, Peking University-Tsinghua University-National Institute Biological Sciences (PTN) Joint Graduate Program, China

2013 北京化工大学 制药工程 学士学位

B.S. Pharmaceutical Engineering, Beijing University of Chemical Technology, China


工作经历 Professional Experience

2023- 北京生命科学研究所 抗体中心主任

Director of Antibody Center, National Institute of Biological Sciences, Beijing

2019-2023 北京生命科学研究所 博士后

Postdoctoral Fellow, National Institute of Biological Sciences, Beijing


发表文章 Publications* co-first author

1. Tian X*, Liu X*, Ding J, Wang F, Wang K, Liu J, Wei Z, Hao X, Li Y, Wei X, Zhang H, Sui J. An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice. Nat Biomed Eng 2023, 7 (1): 8-23.

2. Liu X*, Tian X*, Hao X, Zhang H, Wang K, Wei Z, Wei X, Li Y, Sui J. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Mol Ther Oncolytics 2022, 27: 256-269.

3. Yang F, Zhao L, Wei Z, Yang Y, Liu J, Li Y, Tian X, Liu X, and Sui J. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. J Immunol 2020, 205(8): 2156-2168


抗体中心职能 Antibody Center

北京生命科学研究所抗体中心为研究所的基础科学研究提供多克隆抗体、单克隆抗体和单域抗体等多种抗体的筛选、制备、评估等服务。本中心还可以协助重组蛋白的表达纯化以及活性测定等工作。此外,本中心对靶向病毒、肿瘤相关蛋白、免疫检查点的抗体开发与研究有一定基础,并期待与各实验室合作开发针对其他疾病的诊断或治疗性抗体。

Antibody Center of National Institute of Biological Sciences, Beijing is dedicated to provide services related to development and evaluation of various types of antibodies (including polyclonal antibody, monoclonal antibody, single-chain Fv antibody, bi-specific antibody, and nanobody) for different experiments. We can also assist in design, production, and assessment of fusion proteins. Moreover, we have experience in developing and investigating antibodies targeting viruses, tumor-associated proteins, and immune checkpoints, and we look forward to cooperate with other research groups to develop therapeutic or diagnostic antibodies for other diseases.